Skip to headlines

TECHNOLOGY

Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

TechCrunchWednesday, September 23, 2026 at 7:31 PM

RedScroll Brief

The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.

RedScroll Signal

Impact
High
Category
Technology
Market relevance
Moderate
Why it matters
Technology shifts change how people work, communicate, and build — often faster than policy can follow. The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s. Secondary effects may show up in markets and supply chains linked to Enveda and Technology.

Desk copy

RedScroll Briefing

Extractive editorial brief — not a reprint of the original

What happened

The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.

Why it matters

Technology shifts change how people work, communicate, and build — often faster than policy can follow.

Background

TechCrunch reported on this under technology. RedScroll surfaces the signal with an extractive brief — not a reprint of the original article. Read the source for full reporting.

Timeline

  1. TechCrunch published: Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

  2. Story is in today’s RedScroll edition. Follow the original source for updates.

Economic impact

Secondary effects may show up in markets and supply chains linked to Enveda and Technology.

More on

Related stories

Source

TechCrunch

Original reporting by TechCrunch. RedScroll provides an extractive briefing only.